In this, the second of two Commentaries, Sibylle Gaisser, Michael M. Hopkins and colleagues discuss a survey demonstrating that European health-care systems are ill prepared for the commercial reality of gene patents.
- Sibylle Gaisser
- Michael M. Hopkins
- Dolores Ibarreta